目的 观察与分析不同分子分 型乳腺癌患者磁共振(MRI)及钼靶(CR) 表现，并探讨其与不同分子分型间相关 性。方法 选取80例乳腺癌患者行增强 MRI及钼靶检查，分析患者MRI及钼靶的 影像表现，并于术后将病理组织送检确 定其分子分型，然后分析各分子分型与 MRI及钼靶间关系。结果 经分析发现， (1)Luminal-A型乳腺癌：于MRI及钼靶上 多表现为形态不规则肿块样病变，边缘多 见毛刺且边界模糊，少部分病灶钼靶上见 沙粒样钙化，P<0.05；(2)Luminal-B型乳 腺癌：于MRI及钼靶上多表现为形态不规 则肿块样病变，MR增强后发现大多数不均 匀强化且边缘存毛刺，少部分病灶钼靶上 见沙粒样钙化，P<0.05；(3)三阴性乳腺 癌：MR增强大多呈现环状强化，肿瘤内部 见液化坏死信号，P<0.05；(4)Her2过表 达型：钼靶上病灶沙粒样钙化多见，MRI 增强后肿瘤以周围强化为主，P<0.05。结 论 联合应用MRI及钼靶能鉴别不同类型乳 腺癌，同时影像表现与不同分子分型间存 在较大联系，因此临床可通过观察乳腺癌 患者MRI及钼靶图像表现来初步分析患者 的分子分型，为临床疾病诊断及治疗提供 参考。

Objective To observe and analyze the different molecular subtypes of breast cancer patients with magnetic resonance (MRI) and molybdenum (CR), and to evaluate the effect of different molecular typing methods. Methods The correlation between the 80 breast cancer patients underwent enhanced MRI and mammography, analysis of patients with MRI and mammography imaging findings, and in the postoperative pathological inspection will determine the molecular typing, then analysis and MRI and the relationship between the molybdenum target molecules. Results The results showed that (1) Luminal-A and MRI in breast cancer: mammography showed multiple irregular mass like lesions, edge see burr and boundary fuzzy. A few lesions on mammography see microcalcification, P<0.05. (2) Luminal-B and MRI in breast cancer: mammography showed multiple irregular mass like lesions, MR found that most enhanced uneven enhancement and save edge burr, less lesion mammography see microcalcification, P<0.05. (3) triple negative breast cancer: MR enhancement, most of them showed ring enhancement and tumor see liquefied necrotic signal (P<0.05). (4) there is a strong link between the overexpression of HER2 type: molybdenum target on lesions of sand like calcification, enhanced MRI tumor to the surrounding strengthening (P<0.05). Conclusion combined application of MRI and mammography can identify different types of breast cancer, and imaging manifestations and different molecular typing and clinical observed in breast cancer patients with MRI and mammography performance through preliminary analysis with molecular typing, for clinical diagnosis and treatment of diseases.